HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression.

AuthorsSotirios G Papageorgiou, Vasiliki Pappa, Christina Economopoulou, Panagiotis Tsirigotis, Frida Konsioti, Eleni-Dikaia Ionnidou, Spyros Chondropoulos, Diamantina Vasilatou, Efstathios Papageorgiou, Theofanis Economopoulos, John Dervenoulas
JournalLeukemia research (Leuk Res) Vol. 34 Issue 9 Pg. e254-6 (Sep 2010) ISSN: 1873-5835 [Electronic] England
PMID20392492 (Publication Type: Case Reports, Letter)
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Dasatinib
Topics
  • Antineoplastic Agents (therapeutic use)
  • Benzamides
  • Central Nervous System Neoplasms (secondary)
  • Dasatinib
  • Drug Resistance, Neoplasm
  • Humans
  • Imatinib Mesylate
  • Karyotyping
  • Leukemia, Megakaryoblastic, Acute (drug therapy, genetics, pathology)
  • Male
  • Middle Aged
  • Philadelphia Chromosome
  • Piperazines (therapeutic use)
  • Pyrimidines (therapeutic use)
  • Remission Induction
  • Thiazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: